PCSK9 inhibitors: Going forward and beyond

被引：1
作者：
Attar, Armin [1 ]
机构：
[1] Shiraz Univ Med Sci, Dept Cardiovasc Med, TAHA Clin Trial Grp, Shiraz, Iran
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 08期
关键词：
LDL-CHOLESTEROL; SECONDARY ANALYSIS; CLINICAL-EFFICACY; EVOLOCUMAB; SAFETY; STATIN;
D O I：
10.1177/2047487320916964
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：803 / 804
页数：2
相关论文
共 50 条
  • [41] Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
    Panagiotopoulou, Olga
    Chiesa, Scott T.
    Tousoulis, Dimitrios
    Charakida, Marietta
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (27) : 4494 - 4521
  • [42] PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia
    Verbeek, Rutger
    Stoekenbroek, Robert M.
    Hovingh, G. Kees
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 763 : 38 - 47
  • [43] PCSK9 inhibitors on blue prescription for whom?
    Semb, Anne Grete
    Vesterbekkmo, Elisabeth Kleivhaug
    Retterstol, Kjetil
    Atar, Dan
    Solberg, Erik E.
    Schirmer, Henrik
    Lochen, Maja-Lisa
    Kask, Anne
    Grimsmo, Jostein
    Ingul, Charlotte Bjork
    Munkhaugen, John
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2023, 143 (08) : 680 - 682
  • [44] Are there different responses to different PCSK9 inhibitors?
    Asenjo Mota, A.
    Caamano Selma, O.
    Sanchez-Aquino Gonzalez, R.
    HIPERTENSION Y RIESGO VASCULAR, 2020, 37 (01): : 42 - 44
  • [45] PCSK9 inhibitors - past, present and future
    Reiner, Zeljko
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (10) : 1517 - 1521
  • [46] Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases
    Nejabat, Mojgan
    Hadizadeh, Farzin
    Almahmeed, Wael
    Sahebkar, Amirhossein
    DRUG DISCOVERY TODAY, 2025, 30 (03)
  • [47] Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
    Koskinas, Konstantinos C.
    Wilhelm, Matthias
    Windecker, Stephan
    SWISS MEDICAL WEEKLY, 2016, 146 : w14333
  • [48] PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
    Marco-Benedi, Victoria
    Sanchez-Hernandez, Rosa M.
    Diaz, Jose Luis
    Jarauta, Estibaliz
    Suarez-Tembra, Manuel
    Pinto, Xavier
    Morillas, Carlos
    Plana, Nuria
    Pedro-Botet, Juan
    Civeira, Fernando
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [49] Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives
    Tsouka, Aikaterini N.
    Tellis, Constantinos C.
    Tselepis, Alexandros D.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (31) : 3622 - 3633
  • [50] PCSK9 inhibition: the way forward in the treatment of dyslipidemia
    Robert M. Stoekenbroek
    John JP Kastelein
    Roeland Huijgen
    BMC Medicine, 13
12345